A Phase 3 interventional study of LEO 90100 and Vehicle in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 16th largest by enrollment, is one of 6 that started in 2013, is one of 17 in phase 3, and was the 26th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 426 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 14th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2013, is one of 20 in phase 3, and was the 42nd registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
Drug: LEO 90100
Aerosol foam vehicle
Drug: Vehicle
Drug pages: Calcipotriene · Betamethasone dipropionate
Treatment Success According to IGA
Subjects with 'treatment success' ('clear' or 'almost clear' for subjects with at least moderate disease at baseline, 'clear' for subjects with mild disease at baseline) according to the Investigators' global assessment of disease severity (IGA) at Week 4. The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe
Time frame: 4 weeks
m-PASI at Week 4
The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).
Time frame: 4 weeks
m-PASI at Week 1
The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).
Time frame: 1 week
First Subject First Visit: 17-Jun-2013 Last Subject Last Visit: 02-Oct-2013
| Milestone | LEO 90100 | Vehicle |
|---|---|---|
| Started | 323 | 103 |
| Completed | 313 | 99 |
| Not completed | 10 | 4 |
Subjects with 'treatment success' ('clear' or 'almost clear' for subjects with at least moderate disease at baseline, 'clear' for subjects with mild disease at baseline) according to the Investigators' global assessment of disease severity (IGA) at Week 4. The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe
| percentage of subjects | LEO 90100 | Vehicle |
|---|---|---|
| Treatment Success According to IGA | 53.3 | 4.8 |
The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).
| Scores on a scale | LEO 90100 | Vehicle |
|---|---|---|
| m-PASI at Week 4 | 2.04 (1.74 to 2.35) | 5.33 (4.79 to 5.86) |
The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).
| Scores on a scale | LEO 90100 | Vehicle |
|---|---|---|
| m-PASI at Week 1 | 4.66 (4.41 to 4.90) | 5.93 (5.50 to 6.36) |
Non-serious events are listed at a 0.6% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LEO 90100 | — | 2/323 (0.6%) | 18/323 (5.6%) |
| Vehicle | — | 0/103 (0%) | 15/103 (14.6%) |
| Event | LEO 90100 | Vehicle |
|---|---|---|
| Substance induced psychotic disorderPsychiatric disorders | 1/323 | 0/103 |
| Bipolar disorderPsychiatric disorders | 1/323 | 0/103 |
| Event | LEO 90100 | Vehicle |
|---|---|---|
| Application site painGeneral disorders | 3/323 | 2/103 |
| NasopharyngitisInfections and infestations | 6/323 | 0/103 |
| DiarrhoeaGastrointestinal disorders | 2/323 | 1/103 |
| Eye infectionInfections and infestations | 0/323 | 1/103 |
| Gastroenteritis viralInfections and infestations | 0/323 | 1/103 |
| Streptococcal infectionInfections and infestations | 0/323 | 1/103 |
| Application site drynessGeneral disorders | 0/323 | 1/103 |
| Application site erosionGeneral disorders | 0/323 | 1/103 |
| Application site erythemaGeneral disorders | 0/323 | 1/103 |
| Application site oedemaGeneral disorders | 0/323 | 1/103 |
| Age, Continuous(years) | LEO 90100 | Vehicle | Total |
|---|---|---|---|
| Mean | 51.2 ± 13.9 | 46.0 ± 13.2 | 50.0 ± 13.9 |
| Sex: Female, Male(Participants) | LEO 90100 | Vehicle | Total |
|---|---|---|---|
| Female | 119 | 54 | 173 |
| Male | 204 | 49 | 253 |
Plan to share: No
The record gives a start of Jun 2013, a primary completion of Oct 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 2 years 7 months after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate